for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Company News

BRIEF-Cannimed Therapeutics Q3 loss from cont ops $0.06 per share​

Sept 11 (Reuters) - Cannimed Therapeutics Inc:

* Cannimed Therapeutics Inc. reports financial results for Q3 2017

* Cannimed Therapeutics Inc - for three months ended July 31, 2017, company recorded loss from continuing operations of $1.4 million, or $0.06 per share

* Cannimed Therapeutics-with current, planned cap ex, co is targeting production expansion estimated to reach 17,000 to 21,000 kg within next 24 months

* Q3 sales rose 80 percent to C$4.8 million Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up